This clinical trial is focused on understanding the long-term effects of the medication semaglutide on a condition called diabetic retinopathy in people with type 2 diabetes. Diabetic retinopathy is an eye disease that can occur in individuals with diabetes, potentially leading to vision problems. The study will compare the effects of semaglutide, which is administered as a solution for injection, to a placebo. The purpose of the study is to assess how semaglutide affects the development and progression of diabetic retinopathy when added to the usual care for type 2 diabetes.

Participants in the study will receive either semaglutide or a placebo through a pre-filled pen injector, which allows for easy administration under the skin. The study will take place over several years, during which participants will undergo regular eye examinations to monitor any changes in their condition. These assessments will help determine if semaglutide has a beneficial effect on preventing or slowing down the progression of diabetic retinopathy compared to the placebo.

The study aims to provide valuable insights into the safety and effectiveness of semaglutide for individuals with type 2 diabetes who are at risk of developing diabetic retinopathy. By participating in this research, it is hoped that new information will be gathered to improve the management and treatment of this eye condition in the future.